Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives $78.86 Consensus Price Target from Analysts

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been given an average recommendation of “Moderate Buy” by the eight analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $78.8571.

A number of brokerages recently issued reports on ESTA. Mizuho lifted their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. JPMorgan Chase & Co. upped their price target on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of Establishment Labs from a “sell” rating to a “hold” rating in a research note on Sunday, October 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Finally, Canaccord Genuity Group upped their target price on Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th.

Establishment Labs Stock Down 4.3%

Shares of NASDAQ ESTA opened at $64.63 on Wednesday. Establishment Labs has a 1 year low of $26.56 and a 1 year high of $78.24. The firm has a 50-day simple moving average of $69.75 and a two-hundred day simple moving average of $52.71. The company has a market cap of $1.88 billion, a P/E ratio of -22.76 and a beta of 0.92. The company has a debt-to-equity ratio of 15.06, a current ratio of 3.33 and a quick ratio of 2.10.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, November 5th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.16. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The firm had revenue of $53.78 million for the quarter, compared to analysts’ expectations of $52.28 million. During the same quarter in the prior year, the firm posted ($0.59) earnings per share. The company’s quarterly revenue was up 33.8% on a year-over-year basis. Research analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Hedge funds have recently modified their holdings of the stock. Quarry LP acquired a new position in shares of Establishment Labs in the 3rd quarter valued at $34,000. State of Wyoming purchased a new stake in Establishment Labs during the 3rd quarter valued at about $71,000. Osaic Holdings Inc. increased its holdings in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the period. CWM LLC boosted its position in Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after buying an additional 686 shares during the last quarter. Finally, PharVision Advisers LLC purchased a new position in Establishment Labs during the 3rd quarter worth approximately $203,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.